SCHEMBL4478693

SCHEMBL4478693

COc1ccc(C(F)(F)F)cc1NC(=O)c1ccc(C)c(-n2cc(C(=O)O)cn2)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.50
ABL1 P00519 3/20 0.49
BCR P11274 3/20 0.49
KDM4E B2RXH2 3/20 0.49
TP53 P04637 1/20 0.49
MAPK1 P28482 1/20 0.48
KDR P35968 2/20 0.48
TEK Q02763 2/20 0.48
BRAF P15056 5/20 0.48
HPGD P15428 2/20 0.47
ALDH1A1 P00352 2/20 0.47
KMT2A Q03164 2/20 0.47
HTT P42858 2/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
HSD17B10 Q99714 1/20 0.47
MEN1 O00255 1/20 0.46
CYP1A2 P05177 1/20 0.46
CYP3A4 P08684 1/20 0.46
CYP2C19 P33261 1/20 0.46
POLB P06746 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13935887 0.88 MAPT (0.46) MAPTABL1BCRKDM4ETP53
SCHEMBL4471665 0.83 BRAF (0.50) ABL1BCRBRAF
SCHEMBL4474207 0.81 KDR (0.49) MAPTKDM4ETP53MAPK1KDR
SCHEMBL4478482 0.79 ABL1 (0.41) ABL1BCRBRAFKMT2AMEN1
Pivalamide SCHEMBL5175771 0.79 BRAF (0.47) ABL1BCRBRAF
SCHEMBL12764349 0.79 MAPT (0.65) MAPTKDM4ETP53MAPK1KDR
SCHEMBL4491863 0.79 ABL1 (0.41) ABL1BCRBRAF
SCHEMBL5175779 0.79 BRAF (0.47) ABL1BCRBRAF
SCHEMBL4484455 0.77 ABL1 (0.42) ABL1BCRBRAF
SCHEMBL2952956 0.77 MAPT (0.63) MAPTKDM4ETP53MAPK1KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7485657-B2 Anti-cytokine heterocyclic compounds BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2009-02-03 US claimed
US-20050256113-A1 Anti-cytokine heterocyclic compounds BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2005-11-17 US claimed
US-7485657-B2 Anti-cytokine heterocyclic compounds BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2009-02-03 US disclosed
EP-1756065-A1 ANTI-CYTOKINE HETEROCYCLIC COMPOUNDS BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) 2007-02-28 EP disclosed
WO-2005115991-A1 ANTI-CYTOKINE HETEROCYCLIC COMPOUNDS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2005-12-08 WO disclosed
US-20050256113-A1 Anti-cytokine heterocyclic compounds BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2005-11-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050256113-A1 Anti-cytokine heterocyclic compounds TNF, IL6, IL2 MAPT 3884/4885ABL1 1997/4885BCR 1202/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.